The synthesis of type I collagen, the main component of bone matrix, precedes the expression of Runx2, the earliest determinant of osteoblast differentiation. We hypothesized that the energetic needs of osteoblasts might explain this apparent paradox. We show here that glucose, the main nutrient of osteoblasts, is transported in these cells through Glut1, whose expression precedes that of Runx2. Glucose uptake favors osteoblast differentiation by suppressing the AMPK-dependent proteasomal degradation of Runx2 and promotes bone formation by inhibiting another function of AMPK. While RUNX2 cannot induce osteoblast differentiation when glucose uptake is compromised, raising blood glucose levels restores collagen synthesis in Runx2-null osteoblasts and initiates bone formation in Runx2-deficient embryos. Moreover, RUNX2 favors Glut1 expression, and this feedforward regulation between RUNX2 and Glut1 determines the onset of osteoblast differentiation during development and the extent of bone formation throughout life. These results reveal an unexpected intricacy between bone and glucose metabolism.
INTRODUCTION
The transcription factor RUNX2 is a master determinant of osteoblast differentiation (Long, 2012; Karsenty et al., 2009) . Its expression in prospective osteoblasts precedes osteoblast differentiation; its inactivation prevents osteoblast differentiation; and its haplo-insufficiency causes a skeletal dysplasia called cleidocranial dysplasia (CCD), which is characterized by a delay in osteoblast differentiation, leading to hypoplastic clavicles and open fontanelles. Several aspects of Runx2 biology, however, remain poorly understood. For example, the nature of the molecular events leading to RUNX2 accumulation in cells of the osteoblast lineage is largely unknown. Another question is to determine if and how RUNX2 contributes to bone formation by differentiated osteoblasts. A peculiar feature of osteoblast biology raises this latter issue.
Type I collagen is by far the most abundant protein of bone extracellular matrix (ECM), and its synthesis by osteoblasts is often considered a biomarker of bone formation. Type I collagen is a heterotrimeric protein made of two a1(I) chains and one a2(I) chain, which are encoded by two different genes (Vuorio and de Crombrugghe, 1990) . In vitro, RUNX2 can bind to and upregulate the activity of an a1(I) Collagen promoter fragment (Kern et al., 2001) . However, in vivo type I collagen synthesis precedes Runx2 expression in prospective osteoblasts. Thus, the regulation of type I collagen synthesis in osteoblasts is not fully understood, and by extension, since bone ECM is mainly made of type I collagen, it is also unclear how bone formation by osteoblasts is regulated.
Besides being responsible for bone formation, osteoblasts are endocrine cells that secrete the hormone osteocalcin, which favors glucose homeostasis (Lee et al., 2007) . Notwithstanding the molecular complexity of this emerging regulation, the identification of bone as a regulator of glucose metabolism raises a fundamental question: why would bone have this role? A prerequisite to answering this question is to define the functions of glucose in osteoblasts.
Here, we asked if the energetic needs of the osteoblast might explain how osteoblast differentiation and bone formation occurs in vivo. We found that glucose is the main nutrient of osteoblasts and it is transported in these cells in an insulin-independent manner through the facilitative Glut1 glucose transporter whose expression precedes that of Runx2 during skeletogenesis. By inhibiting one activity of AMPK, glucose is necessary for RUNX2 accumulation and osteoblast differentiation; through the inhibition of another AMPK function, glucose is necessary for collagen synthesis and bone formation. Moreover, by promoting RUNX2 accumulation, glucose uptake in osteoblasts favors Osteocalcin expression and whole-body glucose homeostasis. We further show that RUNX2 is not sufficient for timely osteoblast differentiation and proper bone formation if glucose uptake is compromised, whereas raising blood glucose levels induces collagen synthesis and bone formation in the absence of Runx2. The relationship between RUNX2 and glucose uptake is even more elaborate since RUNX2 is needed for Glut1 expression in osteoblasts. This crosstalk between RUNX2 and glucose uptake acts as an amplification mechanism, allowing osteoblast differentiation and bone formation to be coordinated throughout life. This study provides a bone-centric illustration of the importance of crosstalk between bone and glucose metabolism.
RESULTS

Insulin-Independent Glucose Uptake in Osteoblasts
To determine the main nutrient(s) used by osteoblasts, we measured the oxygen consumption rate (OCR) of osteoblasts when incubated with individual nutrients. Like neurons and unlike myoblasts, osteoblasts had the highest OCR when cultured in the presence of glucose and the lowest when cultured in the presence of a representative fatty acid ( Figure 1A ). These results prompted us to measure, through euglycemic hyperinsulinemic clamps, the amount of glucose taken up by bone and the mechanism by which it occurs in 3-month-old wild-type (WT) mice.
In the conditions of this assay, bone takes up one-fifth of the quantity of glucose taken up by skeletal muscle, the tissue taking up the majority of glucose in the mouse (Ferrannini et al., 1988) , and one-half of what is taken up by white adipose tissue (WAT) ( Figure 1B ). Unlike uptake for skeletal muscle and WAT, glucose uptake in bone is not enhanced by insulin ( Figure 1B ). We also compared the uptake of 2-[U-14 C] deoxyglucose (2-DG) in osteoblasts and osteoclasts to that in myoblasts. Both bone cell types take up approximately one-third of the quantity of 2-DG taken up by myoblasts and do so in an insulin-independent manner ( Figure 1C ). Consistent with these observations, Glut1, which transports glucose in an insulin-independent manner, is expressed two orders of magnitude higher than any other class I glucose transporter in bone cells ( Figure 1D ). The rest of this study focuses on the functions of glucose in osteoblasts.
To establish the biological importance of Glut1 expression in these cells, we analyzed osteoblasts lacking or overexpressing modestly (1.75-fold) Glut1 (Figures S1A and S1B). Glut1À/À osteoblasts took up 75% less 2-DG, and a1(I)Col-Glut1 osteoblasts took up 20% more 2-DG than did control osteoblasts ( Figure 1E ). Consequently, glycogen content was decreased 50% in Glut1À/À and increased 40% in a1(I)Col-Glut1 osteoblasts compared to controls ( Figure S1C ). Thus, GLUT1 is responsible for the majority of glucose uptake in osteoblasts.
Glucose Uptake Is Necessary for Osteoblast Differentiation during Development Next, we analyzed the spatial and temporal pattern of Glut1 expression during skeletogenesis by in situ hybridization and compared it to that of a1(I) Collagen and Runx2, two marker genes of mesenchymal cells and osteoblasts, of a1(II) Collagen, a marker of non-hypertrophic chondrocytes, and of a1(X) collagen, a marker of hypertrophic chondrocytes.
At E10.5 Glut1 is highly expressed in a1(I) Collagen-expressing mesenchymal cells of the developing hindlimbs (Figures 1Fa-1Fj ). Runx2 is expressed in a1(I) Collagen/Glut1-expressing cells at E12.5 and is expressed in these cells throughout development (Figures 1Fk-1Fo ). Prior to E12.5, another Runx gene, Runx1, is expressed in a1(I) Collagen/Glut1-expressing cells (Figures 1Fp-1Ft ). The third Runx gene, Runx3, is not expressed before E13.5, and its expression is predominant in a1(II) Collagen-expressing chondrocytes (Figures 1Fu-1Fy and 1Fz-1Fb1) . Glut1 is virtually not expressed in chondrocytes (Figures 1Fa-1Fe and 1Fz-1Fe1) . In view of this pattern of expression, we analyzed the function of Glut1 during osteoblast differentiation by crossing mice harboring a floxed allele of Glut1 ( Figure S2A ) with mice expressing the Cre recombinase under the control of Dermo1 (Glut1 dermo1 À/À), which deletes genes starting at E12.5, or of Osterix regulatory elements (Rodda and McMahon, 2006) (Glut1 osx À/À), which deletes genes starting at E14.5. We verified in each case that Glut1 was efficiently deleted in the targeted cells, but not in other cell types or tissues, and that expression of other Gluts was not affected by the Glut1 deletion ( Figures  S2B-S2E ).
Using alcian blue/alizarin red staining of skeletal preparations to distinguish non-mineralized (blue) from mineralized ECM (red), Glut1 dermo1 À/À and control embryos were indistinguishable until E13.5 ( Figure S2F ). E14.0 was the first time point at which a delay in ECM mineralization in long bones and the jaws was seen in Glut1 dermo1 À/À embryos ( Figure 2A ). This difference in ECM mineralization between control and Glut1 dermo1 À/À embryos was verified histologically ( Figure 2B ). At E14.5, ECM mineralization was still absent in the mandibles of Glut1 dermo1 À/À embryos ( Figure 2A ). Beyond E14.5, we also studied Glut1 osx À/À embryos. At E15.5, a large area of mineralized ECM was present in the axial skeleton of controls, but not in that of Glut1 osx À/À and Glut1 dermo1 À/À embryos, except in long bones (Figures 2C and S2F) . Von Kossa staining of histological sections detected extensive ECM mineralization in skeletal elements of control embryos, while this mineralization was more restricted in Glut1 osx À/À embryos; alcian blue staining of these sections showed that ECM in Glut1 osx À/À skeletal elements was mostly of cartilaginous nature ( Figure 2D ). Consistent with this observation, a1(X) Collagen-expressing hypertrophic chondrocytes covered a larger area in Glut1 osx À/À than in control skeletal elements, and expression of Osteocalcin was undetectable in Glut1 osx À/À skeletal elements ( Figure 2E ), indicating that osteoblast differentiation was delayed in E15.5 Glut1 osx À/À embryos. Remarkably, despite these delays in osteoblast differentiation and bone formation, Runx2 and a1(I) Collagen were normally expressed in E15.5 Glut1 osx À/À skeletal elements ( Figure 2E ).
At E18.5, Glut1 osx À/À embryos' skulls, which ossify mostly through an intramembranous process, were poorly mineralized, suggesting that osteoblast differentiation was delayed ( Figure 2F ). Von Kossa staining of histological sections showed numerous long, thick trabeculae in controls, but not in Glut1 osx À/À, long bones, and an alcian blue staining showed many more cartilaginous remnants in Glut1 osx À/À than in control skeletal elements ( Figure 2G ). Accordingly, the area occupied by a1(X) Collagenexpressing hypertrophic chondrocytes remained larger in Glut1 osx À/À than in control skeletal elements, and expression of Osteocalcin was still barely detectable ( Figures 2H-2J ). This incomplete osteoblast differentiation in Glut1 osx À/À bones and osteoblasts was further illustrated by the decreased expression of Bsp ( Figures 2I and 2J ). This delay in osteoblast differentiation explains why E18.5 Glut1 osx À/À embryos had open fontanelles and hypoplastic clavicles ( Figure 2F ). Even though these two (A) Oxygen consumption rate (OCR) of osteoblasts, C2C12 myoblasts, or hippocampal neurons incubated with vehicle, 10 mM glucose, 2 mM glutamine, or 300 mM palmitate in 13 Krebs-Henseleit buffer for 2 hr (n = 8). (B) Glucose uptake measured by euglycemic hyperinsulinemic clamps in femurs, white adipose tissue, and gastrocnemius muscle of WT mice before or after insulin infusion (2.5 mU/kg/min) (n = 4). (C) Uptake rate of 2-DG in osteoblasts (Osb), osteoclasts (Ocl), and myoblasts (n = 3).
(D) Expression of class I Gluts in osteoblasts and osteoclasts assayed by qPCR. (E) Uptake rate of 2-DG in Glut1fl/fl, Glut1À/À, WT, and a1(I)Col-Glut1 osteoblasts (n = 6-8). (F) In situ hybridization analysis of Glut1 (a-e), a1
, and a1(X) Collagen (c1-e1) in hindlimbs during embryonic development. All error bars represent SEM. See also Figure S1 . (legend continued on next page) features are characteristic of CCD, a disease caused by the decreased function of RUNX2 (Mundlos et al., 1997; Lee et al., 1997) , Runx2 expression was normal in E18.5 Glut1 osx À/À bones. The same was true for a1(I) Collagen expression ( Figures 2H-2J ). Accounting for this delay in osteoblast differentiation and CCD phenotype, there was a 70% decrease in RUNX2 accumulation in E18.5 Glut1 osx À/À bones and osteoblasts ( Figure 2K ). This decrease in RUNX2 accumulation was not observed for other transcription factors ( Figure S2G ). There was also a 70% decrease in type I collagen accumulation in E18.5 Glut1À/À bones and osteoblasts because of a 60% decrease in the rate of collagen synthesis in Glut1À/À compared to control osteoblasts ( Figures 2K and 2L ). This latter finding explained the decreased bone formation in Glut1 osx À/À embryos. Of note, Chrebp, a transcriptional mediator of glucose signaling in other cell types (Yamashita et al., 2001) , is not expressed and does not regulate glucose uptake in osteoblasts ( Figures S2H-S2K ).
Glucose Uptake in Osteoblasts Is Necessary for Bone Formation and Whole-Body Glucose Homeostasis Post-natally To study Glut1 functions in osteoblasts post-natally, we crossed Glut1fl/fl mice with Osteocalcin-Cre mice (Glut1 ocn À/À) that do not initiate gene deletion before E18.5 and performed an inducible deletion of Glut1 in osteoblasts in 6-week-old Osx-Cre;Glut1fl/fl mice (Glut1 Dox À/À). After verifying the specificity and efficiency of the gene deletions (Figures S3A and S3B), we examined both models of Glut1À/À mice at 3 months of age and included in this analysis a1(I)Col-Glut1 mice that modestly overexpress (1.75-fold) Glut1 in osteoblasts ( Figure S2D ).
Glut1 ocn À/À and Glut1 Dox À/À mice of either sex presented with a low bone mass in all bones analyzed, whereas a1(I)ColGlut1 mice displayed a high bone mass. In these mouse models, only the parameters of bone formation, i.e., circulating levels of PINP, mineral apposition rate, bone formation rate, and number of osteoblasts, were affected . Expression of the cell-cycle regulators Ccnd2, Ccne1, and Cdk4 and osteoblast proliferation as measured by bromodeoxyuridine (BrdU) incorporation were decreased in Glut1 ocn À/À and increased in a1(I)Col-Glut1 bones ( Figures 3D and 3E) . Again, accumulation, and not expression, of RUNX2 and type I collagen was decreased in Glut1 ocn À/À and increased in a1(I) Col-Glut1 bones (Figures 3F and 3G) .
Following fluctuating RUNX2 accumulation, expression of Osteocalcin, a RUNX2 target gene, and circulating osteocalcin levels were low in Glut1 ocn À/À mice and high in a1(I)Col-Glut1 compared to control mice (Figures 3F and S3F) . As a result, insulin secretion after glucose stimulation, glucose tolerance measured by a glucose tolerance test, insulin sensitivity assessed by an insulin tolerance test (ITT), and the steady-state glucose infusion rate during euglycemic-hyerpinsulinemic clamp were suppressed in Glut1 ocn À/À mice and improved in a1(I)ColGlut1 compared to control mice ( Figures 3H-3N ). In summary, glucose uptake in the cells of the osteoblast lineage is necessary for osteoblast differentiation, bone formation, and whole-body glucose homeostasis.
Glucose Uptake Favors Osteoblast Differentiation and Bone Formation by Inhibiting AMPK
To determine if the delay in osteoblast differentiation and the decrease in bone formation seen in Glut1 osx À/À embryos and mice were due to a decrease in protein synthesis that a poor glucose uptake triggers (Jeyapalan et al., 2007; Mayer et al., 2011) , we measured AMP, ADP, and ATP contents in Glut1À/À osteoblasts.
Although AMP and ATP levels were not affected, there was a 3-fold increase in ADP content, leading to a 3-fold increase in the ratio of ADP to ATP in Glut1À/À versus control osteoblasts ( Figures 4A and S4A) . As a result, AMPK activity, assessed by the phosphorylation of its a subunit at Thr172 and of its substrate ACC1 at Ser79 (Woods et al., 1994; Wilson et al., 1996) , was increased ( Figure 4B ). Several lines of evidence indicated that the activity of the mTORC1 complex was decreased in Glut1À/À osteoblasts. Phosphorylation of the mTORC1 substrates p70S6K at Thr389, 4E-BP1 at Thr37, and eIF4G at Ser1108 was decreased (Bolster et al., 2002; Reiter et al., 2005) (Figure 4C) ; Raptor phosphorylation at Ser792 was increased; and mTORC1 kinase activity was decreased in Glut1À/À osteoblasts ( Figures 4B and 4D) . Conversely, p70S6K phosphorylation and collagen accumulation were both decreased in RaptorÀ/À osteoblasts, and knockdown of Tsc1 and Tsc2 not only restored mTORC1 activity as measured by p70S6K phosphorylation but also normalized collagen accumulation in Glut1À/À osteoblasts ( Figures 4E and 4F) .
To demonstrate that the decrease in mTORC1 activity and the phenotypes of the Glut1 osx À/À mice are caused by an increase in AMPK activity in osteoblasts, we decreased the expression of Ampk in osteoblasts by generating Glut1À/À embryos or mice lacking in osteoblasts one allele of Ampka1, the most highly expressed AMPKa subunit in these cells ( Figure 4G ). Phosphorylation of AMPKa1 and p70S6K, ATP contents, RUNX2, and type I collagen accumulations were similar in Glut1 osx À/À; Ampka1 osx +/À and control osteoblasts, indicating that AMPK activity and therefore mTORC1 signaling had been restored in Glut1 osx À/À;Ampka1 osx +/À osteoblasts ( Figures 4H, S4B , and (F) Alcian blue/alizarin red staining of skeletal preparations of E18.5 Glut1 osx À/À, Glut1fl/fl, and Osx-cre embryos. (G) Von Kossa or alcian blue staining of femur from E18.5 Glut1 osx À/À, Glut1fl/fl, and Osx-cre embryos. (H) In situ hybridization analysis of Osteocalcin, a1(I), a1(X) Collagen, and Runx2 expression in E18.5 Glut1 osx À/À and Glut1fl/fl femurs. (I) Expression of osteoblast markers in E18.5 Glut1 osx À/À and Glut1fl/fl femurs (n = 9). (J) Expression of osteoblast marker genes in Glut1fl/fl and Glut1À/À osteoblasts (n = 6). (K) a1(I) Collagen and RUNX2 accumulations in E18.5 Glut1 osx À/À and Glut1fl/fl femurs and Glut1fl/fl and Glut1À/À osteoblasts. (L) 3 H-proline incorporation into collagen of Glut1fl/fl and Glut1À/À osteoblasts (n = 6).
All error bars represent SEM. See also Figure S2 . (legend continued on next page) S4C). As a result, alcian blue/alizarin red staining of skeletal preparations, histological, and in situ hybridization analyses showed normal osteoblast differentiation and no evidence of CCD in Glut1 osx À/À;Ampka1 osx +/À embryos ( Figures 4I-4L ). Bone formation parameters were also normal in Glut1 ocn À/À; Ampka1 ocn +/À mice ( Figure 4M) . Two experiments showed that increasing AMPK activity in osteoblasts is deleterious for bone. Treating mouse osteoblasts with AICAR, an AMPK agonist, profoundly decreased type I collagen and RUNX2 accumulations in these cells, and WT mice treated with AICAR from 6 to 14 weeks of age showed a significant decrease in bone formation parameters and bone mass ( Figures 4N and 4O) . Accordingly, and as is the case for Glut1À/À osteoblasts, WT osteoblasts deprived of glucose had higher levels of P-AMPK and lower levels of P-P70S6K and type I collagen than if cultured in the presence of glucose ( Figure S4D ).
Runx2 Cannot Induce Osteoblast Differentiation when Glucose Uptake Is Hampered
In the course of these experiments, we noticed that RUNX2 accumulation was restored when Glut1À/À osteoblasts were treated with an inhibitor of proteasome degradation and that RUNX2 ubiquitination was increased in Glut1À/À osteoblasts ( Figure 5A ). Normal RUNX2 ubiquitination in Glut1À/À; Ampka1+/À and Glut1À/À;Ampka1À/À osteoblasts ( Figure 5B ) implicated AMPK in RUNX2 polyubiquitination. Mass spectrometry and bioinformatics analyses identified a possible AMPK recognition site in SMURF1, an E3 ubiquitin ligase involved in RUNX2 degradation (Zhao et al., 2003) (Figures S5A and S5B) . In vitro, AMPK phosphorylated SMURF1 at Ser148, and this phosphorylation event was needed for SMURF1-induced RUNX2 ubiquitination ( Figures 5C and 5D ). SMURF1 phosphorylation at Ser148 did not increase in Ampka1À/À osteoblasts, and RUNX2 accumulation did not decrease in Ampka1À/À or Smurf1À/À osteoblasts cultured in the absence of glucose as it did in WT osteoblasts ( Figures 5E and 5F ). Moreover, an antiphospho-SMURF1 antibody demonstrated AMPKa1 interaction with phospho-SMURF1 in Glut1À/À osteoblasts and that SMURF1 phosphorylation at S148 was higher in Glut1À/À than in control, Glut1À/À;Ampka1+/À, and Glut1À/À;Ampka1À/À osteoblasts ( Figures 5G and 5H) . These results indicate that AMPK favors RUNX2 proteasomal degradation by phosphorylating SMURF1.
This unanticipated regulation of RUNX2 ubiquitination by AMPK allowed selectively assessing the ability of RUNX2 to induce osteoblast differentiation when glucose uptake is compromised. This was achieved by generating Glut1 osx À/À embryos and Glut1 ocn À/À mice lacking one allele of Smurf1. This manipulation normalized RUNX2 accumulation but did not restore mTORC1 signaling since p70S6K phosphorylation and type I collagen synthesis remained low in Glut1 osx À/À; Smurf1+/À osteoblasts ( Figures 5I and 5J) . As a result, and despite a normal accumulation of RUNX2, skeletal development was equally delayed in Glut1 osx À/À;Smurf1+/À and Glut1 osx À/À embryos at E15.5 and E18.5 (Figures 5K and 5L) . The cartilaginous area and the zone of a1(X)Col-expressing cells were as enlarged in Glut1 osx À/À;Smurf1+/À embryos as in Glut1 osx À/À embryos ( Figures 5M and 5N) . Hence, RUNX2 cannot induce proper osteoblast differentiation during embryogenesis if glucose uptake is hampered because protein synthesis is decreased ( Figure 5O ). Likewise, Glut1 ocn À/À;Smurf1+/À mice were as osteopenic as Glut1 ocn À/À mice ( Figure S5C ).
Glucose Can Initiate Bone Formation in Runx2-Deficient Embryos Next, we asked if conversely, raising the extracellular concentration of glucose was sufficient to initiate type I collagen synthesis in Runx2-deficient osteoblasts. To that end, Runx2fl/fl osteoblasts were infected with a Cre-expressing adenovirus ( Figure S6A) ; these Runx2-/-osteoblasts were then cultured in a differentiation medium containing either 5 or 10 mM glucose.
In Runx2À/À osteoblasts cultured in the presence of 5 mM glucose, GLUT1 accumulation and glucose consumption rate were decreased, phosphorylation of AMPKa1 was high, and phosphorylation of p70S6K was low, indicating that mTORC1 signaling was inhibited. As a result, 3 H-proline incorporation into collagen molecules and accumulation of type I collagen were both lower in Runx2À/À than in control osteoblasts (Figures 6A-6C ). In contrast, when the glucose concentration in the culture medium of Runx2À/À cells reached 10 mM, the glucose consumption rate doubled, and phosphorylation of AMPKa1 and p70S6K, the incorporation rate of 3 H-proline into collagen molecules, and the accumulation of type I collagen were normalized in Runx2À/À cells, even though type I Collagen gene expression did not changed ( Figures 6A-6D ).
In view of these results, we asked whether chronic hyperglycemia would improve bone formation in Runx2+/À embryos. This was achieved by injecting streptozotocin (STZ; 150 mg/kg) into Runx2+/À female mice as soon as a vaginal plug was seen. By decreasing the number of b cells and circulating insulin levels, this manipulation caused a severe hyperglycemia in E18.5 embryos ( Figure 6E ). We focused our analysis on bones forming through intramembranous ossification because they are the ones in which osteoblast differentiation is hampered by Runx2 haplo-insufficiency. While no difference was seen in WT embryos carried by STZ-treated mothers ( Figure S6B ), alcian blue/alizarin red staining of skeletal preparations showed that clavicles of E18.5 Runx2+/À embryos carried by STZ-treated mothers were twice as long as those of Runx2+/À embryos carried by vehicle-treated mothers (1.78 ± 0.08 mm and 0.85 ± 0.05 mm). Interparietal bones were also 2-fold larger in Runx2+/À embryos carried by STZ-treated mothers (2.09 ± 0.12 mm 2 and 1.01 ± 0.13 mm 2 ) than in those carried by control mothers, and the fontanelles of these embryos were less open than were those of Runx2+/À embryos carried by vehicle-treated mothers ( Figures 6F and 6G ). Histological analyses showed the presence of mineralized bone trabeculae in the clavicles of E18.5 Runx2+/À embryos carried by STZ-treated mothers (Figures 6H and 6I ). An immunohistochemistry analysis showed the presence of type I collagen molecules in the clavicles of Runx2+/À embryos carried by STZ-treated mothers, whereas only type X collagen molecules were present in those of Runx2+/À embryos carried by vehicle-treated mothers (Figure 6J ). Accumulation of type I collagen was also increased in the long bones of Runx2+/À embryos carried by STZ-treated mothers ( Figures 6K and 6L ). To further link the rescue of bone phenotype in Runx2-deficient embryos to the increase in blood glucose levels, we repeated this experiment using lower doses of STZ (50 or 100 mg/kg). One hundred milligram per kilogram of STZ was toxic for b cells since it decreased circulating insulin levels nearly 2-fold without raising blood glucose levels in the mothers or embryos ( Figure 6E ). This STZ dose did not correct the delay in bone development of Runx2-deficient embryos (Figures 6F and 6G). Thus, raising blood glucose levels normalized collagen synthesis and enhanced bone formation in Runx2+/À osteoblasts and embryos. Although type I collagen accumulation was also normalized in skeletal elements obtained from Runx2À/À embryos carried by STZ-treated mothers ( Figure 6M ), alcian blue/alizarin red staining of skeletal preparations failed to show any ECM mineralization in the skeletons of E18.5 Runx2À/À embryos carried by STZ-treated mothers ( Figure S6C ). This is probably explained by the fact that RUNX2 regulates the expression of Alkaline Phosphatase (Akp2), a gene necessary for bone mineralization (Murshed et al., 2005) (Figures 6D and 6N ).
Crosstalk between Runx2 and Glut1 Coordinates Osteoblast Differentiation and Bone Formation The results presented above delineated the influence of glucose uptake on osteoblast differentiation and bone formation but did not explain how these two events are coordinated in vivo. In addressing this question we interpreted the fact that Glut1 expression and glucose uptake were decreased in Runx2+/À bones ( Figures 7A and 7B ) as suggesting that RUNX2 regulates Glut1 expression. Runx1 expression in Glut1/a1(I) Collagen-expressing cells of the limb buds prompted us to test if Runx1 could trans-activate the Glut1 promoter.
The Glut1 promoter of the mouse and other vertebrate species has a canonical Runx binding site at À811 bp ( Figure 7C ). Chromatin immunoprecipitation assays verified that RUNX2 binds to this site ( Figure 7D ), and DNA co-transfection experiments performed in COS cells showed that Runx2 or Runx1 expression vectors could increase the activity of a Glut1 promoter-luciferase reporter construct (pGlut1-Luc) only if this site was intact (Figure 7E ). In agreement with these results, expression of Glut1 was decreased in Runx2À/À and increased in Schnurri-3À/À osteoblasts (Shn3À/À) that display an increase in RUNX2 activity (Figures 7F and S7A) . These results explain why glucose uptake and mTORC1 activity were decreased in Runx2À/À and increased in Shn3À/À osteoblasts ( Figures 6B  and 7G) .
If the feedforward regulation between GLUT1-dependent glucose uptake and RUNX2 provides an explanation for the coordination of osteoblast differentiation and bone formation, Glut1 osx +/À;Runx2+/À embryos should display a delay in osteoblast differentiation similar to that of Runx2À/À embryos. Alcian blue/alizarin red staining of skeletal preparations showed that Glut1 osx +/À;Runx2+/À embryos were indistinguishable from Runx2À/À embryos until E16.5 ( Figures 7H and S7B) . At E18.5, clavicles were barely detectable, and most of the bones forming the skull were absent or severely hypoplastic in Glut1 osx +/À;Runx2+/À embryos ( Figure 7I ). Alcian blue staining of histological sections of long bones showed an enlargement of the area of hypertrophic chondrocytes and a cartilaginous ECM in E18.5 Glut1 osx +/À;Runx2+/À embryos ( Figure 7J ). Osteocalcin expression was undetectable in E18.5 Glut1 osx +/À; Runx2+/À skeletal elements, while it was present in single heterozygous embryos. Conversely, the area covered by a1(X) Collagen-expressing cells was greatly enlarged in E18.5 Glut1 osx +/À;Runx2+/À embryos ( Figure 7K ). The extent of the delay in osteoblast differentiation in Glut1 osx +/À;Runx2+/À embryos and mice explained why they all died peri-natally. This crossregulation between Runx2 and Glut1 also determined the extent of bone formation since 3-month-old Glut1 ocn +/À; Runx2+/À mice had a low bone mass not seen in either Glut1 ocn +/À or Runx2+/À mice ( Figure 7L ). Accounting for this severe phenotype, and in agreement with the feedforward loop between glucose uptake in osteoblasts and RUNX2, accumulation of GLUT1, type I collagen, and RUNX2 was decreased more than 80% and phosphorylation of AMPK and SMURF1 was increased in Glut1 osx +/À; Runx2+/À compared to single heterozygous bones ( Figure  7M ). Hence, crossregulation of RUNX2 and Glut1 is an amplification mechanism that determines the onset of osteoblast differentiation and the extent of bone formation throughout life. We also treated Runx2+/À mothers with STZ (150 mg/kg) as soon as a vaginal plug was observed. This dose of STZ raised blood glucose levels in mothers and embryos ( Figure  S7C ) and increased bone formation in skeletal elements of the skull and in clavicles in Glut1 osx +/À;Runx2+/À embryos ( Figure 7N ).
DISCUSSION
This study identifies glucose uptake in prospective osteoblasts as the earliest determinant of osteoblast differentiation and bone formation. It also shows that the coordination of osteoblast differentiation and bone formation throughout life is maintained by a feedforward regulation between glucose uptake in osteoblasts and RUNX2 accumulation. In addition, glucose uptake in osteoblasts is necessary for whole-body glucose homeostasis.
The Bases of the Coordination between Osteoblast Differentiation and Bone Formation A striking feature of bone biology that has never been explained is that the synthesis of the main constituent of bone ECM, type I collagen, precedes the expression of, and is not regulated by, RUNX2, the earliest transcriptional determinant of osteoblast differentiation. This apparent disconnect between osteoblast differentiation and type I collagen synthesis in the bone could be explained by a single mechanism controlling both aspects of osteoblast biology and acting upstream of RUNX2. Our results suggest that this is the case and that this mechanism is glucose uptake in osteoblast progenitor cells. Glucose is the main nutrient of osteoblasts and is taken up by these cells in an insulin-independent manner through Glut1, whose expression precedes that of Runx2. Glucose uptake in osteoblasts favors osteoblast differentiation and bone formation through two distinct mechanisms. First, by inhibiting the activity of AMPK, glucose uptake enhances the activity of the mTORC1 pathway and therefore protein synthesis. Second, and unexpectedly, glucose uptake inhibits another function of AMPK documented here: its ability to favor RUNX2 ubiquitination in part via SMURF1. The two distinct functions of AMPK in osteoblasts revealed here explain why agonists of AMPK activity exert a deleterious influence on bone formation in vivo.
The Glut1-Runx2 pathway described here could have clinical relevance. For instance, Glut1 osx À/À embryos develop CCD, a disease most often caused by a decrease in RUNX2 expression. However, a significant number of CCD patients do not have any detectable mutations in Runx2 (Puppin et al., 2005; Tessa et al., 2003) . Conceivably, in some of these patients, CCD may be caused by a decrease in glucose uptake or utilization in osteoblasts. If this were the case, it would further support the notion that skeletal dysplasia may have a nutritional basis (Elefteriou et al., 2006) . Moreover, the predilection of osteoblasts for glucose demonstrated here provides a plausible explanation for why children chronically fed a ketogenic diet experience poor longitudinal growth (Groesbeck et al., 2006) .
The Respective Functions of Glucose Uptake and Runx2 in Osteoblasts
Remarkably, restoring RUNX2 accumulation in Glut1À/À cells did not translate into efficient bone formation in vivo simply because in osteoblasts unable to properly take up glucose, protein synthesis remains low regardless of the level of expression of Runx2. On the other hand, raising the extracellular concentration of glucose was sufficient to initiate bone formation even though osteoblasts were not fully differentiated in Runx2+/À embryos. Raising blood glucose levels in Runx2À/À embryos also increased collagen synthesis but that did not translate into the presence of a mineralized bone ECM because expression of Akp2, a gene necessary for bone ECM mineralization, is low in the absence of Runx2. Thus, RUNX2 is necessary for osteoblast differentiation and bone ECM mineralization, but not for, paradoxically, the synthesis of the main constituent of this ECM. In broader terms, the importance of glucose uptake in osteoblast differentiation described here raises the hypothesis that glucose uptake may be a more general determinant of cell differentiation during embryonic development. This may be particularly relevant for tissue like muscle that uptakes large amounts of glucose. Independently of its regulation of bone formation, glucose uptake in osteoblasts is necessary for another cardinal function of bone: the regulation of whole-body glucose metabolism. Indeed, through its regulation of RUNX2 accumulation, glucose favors expression of the hormone osteocalcin.
The Synergistic Functions of Glucose Uptake and Runx2 in Osteoblasts
How is osteoblast differentiation and bone formation coordinated throughout life? The fact that Runx2À/À and Glut1À/À osteoblasts had a similar metabolic profile suggested that this coordination might be explained if Glut1 was a target gene of RUNX2.
In support of this hypothesis, both molecular and genetic evidence identifies RUNX2 as a major regulator of Glut1 expression and glucose uptake in osteoblasts. As a result, Runx2À/À osteoblasts bear metabolic similarities with Glut1À/À osteoblasts; Glut1 osx +/À;Runx2+/À embryos are similar to Runx2À/À embryos; and Glut1 ocn +/À;Runx2+/À mice display an osteopenia not seen in either Runx2+/À or Glut1 ocn +/À mice. Hence, the reciprocal regulation between GLUT1-mediated glucose uptake and RUNX2 acts as an amplification chamber that determines the onset of osteoblast differentiation and the extent of bone formation throughout life. In addition, Runx1 expression in the developing skeleton suggests that this Runx protein may regulate Glut1 expression and thereby favor type I collagen accumulation in prospective osteoblasts before E12.5.
In broader terms, the results of this study cannot be separated from the recently described role of osteoblasts in maintaining glucose homeostasis in physiological and pathological situations (Lee et al., 2007; Ferron et al., 2010; Wei et al., 2014) . The absolute necessity of glucose uptake for osteoblast differentiation, bone formation, and glucose homeostasis documented here illustrates, from the perspective of osteoblasts, the fundamental importance of crosstalk between bone and glucose metabolism.
EXPERIMENTAL PROCEDURES Mice Generation
To generate Glut1fl/+ mice, a targeting vector harboring two LoxP sites flanking exons 3-10 of Glut1 were electroporated into embryonic stem cells (ES cells) (CSL3,129/SvEvTac) ( Figure S2A ). Targeted ES cells were detected by Southern blots and injected in 129Sv/EV blastocysts to generate chimeric mice. Chimeric mice were crossed with Gt(ROSA)26Sor tm1(FLP1)Dym mice to re-
Cell Culture Mouse calvaria osteoblasts were isolated and cultured as described previously (Ducy and Karsenty, 1995) . Osteoclast precursors (monocytes) were isolated by culturing bone marrow cells with aMEM/10% fetal bovine serum (FBS) containing M-CSF (10 ng/ml) for 6 days and then treated with RANKL (30 ng/ml) and M-CSF (10 ng/ml) for 7 days. C2C12 myoblasts (ATCC), the mHippoE-14 embryonic mouse hippocampal hypothalamic cell line (Cellutions Biosystems), and COS-7 cells were cultured in DMEM/10% FBS. 
Molecular Biology and Biochemistry
For quantifying gene expression, RNA samples were extracted using TRIZOL reagent (Invitrogen). One to two micrograms of total RNA were converted into cDNA using M-MLV reverse transcriptase (Invitrogen). qPCR analyses were performed using CFX-Connect real-time PCR system (Bio-Rad). Relative expression levels of each gene were normalized to the levels of 18S rRNA or b-actin. Western blot analyses were carried out using standard protocols. All antibodies were obtained from Cell Signaling Technology, except for the anti-GLUT1 (EMD Millipore), anti-COL1A1, anti-RUNX2, anti-SMURF1 (Santa Cruz), anti-Phospho-Ser148 SMURF1 (Genescript), and anti-b-ACTIN (Sigma). Quantification of western blots was performed using ImageJ. Protein levels were quantified and normalized to ACTIN or GADPH levels. Relative protein levels were calculated with respect to control samples. All western blot experiments were repeated at least three times, with different samples.
Glucose Consumption and Uptake Assay
For glucose consumption measurements, following 16-hr incubation with osteoblasts, the glucose concentration in the culture medium was assayed with a Glucose Assay Kit (Biovision). Glucose uptake was determined by the uptake rate of 2-[U-14 C] deoxyglucose (2-DG) in cells. Following a 1-hr fast in glucosefree Krebs-Ringer HEPES (KRH) buffer (50 mM HEPES [pH 7.4], 136 mM NaCl, 4.7 mM KCl, 1.25 mM MgSO 4 , 1.25 mM CaCl 2 , and 0.1% BSA), cells were cultured in KRH buffer containing 100 mM 2-deoxyglucose and 0.5 mCi/ml 2-14 C-DG (287 mCi/mmol, Perkin Elmer, NEC495A) for 1 hr. For glucose uptake in bones, 10 mCi of 2-14 C-DG were immunoprecipitate injected in mice at a random feed state for 1 hr, and calvariae were then collected for analysis. The amount of 2-14 C-DG in total cell or bone lyses was quantified by liquid scintillation counter (WALLAC 1409) and normalized to protein content (Bio-Rad).
Skeleton Preparation, Bone Histology, and In Situ Hybridization Skeleton preparations and alcian blue/alizarin red staining were carried out according to standard protocols (McLeod, 1980) . Bone histology analyses, including Von Kossa staining and alcian blue staining, were performed with histological sections of femurs or clavicle bones using standard protocols. For all skeletal analyses, at least three litters for each embryonic stage and at least five embryos for each genotype were examined. Bone histomorphometry analyses were performed on L3 and L4 vertebrae as described previously (Chappard et al., 1987; Parfitt et al., 1987) . Von Kossa/van Gieson staining, toluidine blue staining, and calcein double-labeling were performed to measure mineralized bone volume over the total tissue volume (BV/TV), osteoblast number per tissue area (N.Ob/T.Ar), mineralization apposition rate (MAR), and bone formation rate per bone surface (BFR/BS). For in situ hybridization, tissues were fixed in 4% paraformaldehyde/PBS overnight at 4 C and then embedded in paraffin after dehydration and sectioned at 5 mm. In situ hybridization was performed using 35 S-labeled riboprobe as described . The
Runx1, Runx3, Runx2, a1(I)Col, a 1(II)Col, a 1(X)Col, Osteocalcin, and Bsp probes have been previously described (Takeda et al., 2001) . The Glut1 probe is a 500-bp fragment of the Glut1 3 0 UTR (see the Supplemental Experimental
Procedures for sequence information). Hybridizations were performed overnight at 55 C, and washes were performed at 63 C.
Statistics
All data are presented as mean ± SEM. Statistical analyses were performed using unpaired, two-tailed Student's t test for comparison between two groups, and an ANOVA test was used for experiments involving more than two groups. For all experiments, * denotes p % 0.05, and # denotes p % 0.001 compared to control. 
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